Editas Medicine : May 2025 Corporate Presentation (684bf7)

Published: 2025-05-28 16:22:07 ET EDIT

Published on 05/28/2025 at 16:22

Stephanie and Tristan

Pioneering the Possible in Gene Editing

1

May 2025

that mobile smart phones have transformed the communications business around the world.

Problem Solution

Recent slow launches

Low total addressable markets (TAMs)

Reimbursement challenges

High cost of goods

Low margins

Highly complex patient journeys

Curative business model

Many recent gene therapy launches pursued competitive indications with already high standards of care

Differentiated therapeutic approach to diseases

Diseases with higher TAMs

Simple, scalable, lower cost of goods

High margin in vivo delivery methods

Ability to treat more patients with less burdensome treatment regimen

Sustainable revenue growth for curative medicines through rapid development of therapies

A different approach focused on functional upregulation treatment strategy (proven by reni-cel).

Solved for delivery using proprietary, targeted LNPs (tLNPs) that allow targeting of multiple tissues, including HSCs, liver, and other tissues using "plug 'n play" process.

Defined path to rapid development of new medicines with "plug 'n play" in vivo editing using reprogrammable guide RNA by changing 20 nucleotides to create a new product for a new disease target.

A leading gene editing platform supported by foundational IP estate.

Driven management team with a proven track record of drug development and commercialization, strong domain expertise, and focus on execution.

Strong cash position with operational runway into Q2 2027.

Disclaimer

Editas Medicine Inc. published this content on May 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 28, 2025 at 20:21 UTC.